Podcasts about clinical solutions

In this episode, IQVIA MedTech experts Michelle Edwards and Michaela Miller discuss key trends shaping the MedTech industry in 2025. The conversation covers advancements in 3D printing, real-world evidence (RWE), and clinical AI, among others. Read Ten MedTech Trends to Watch in 2025 to learn more. https://www.iqvia.com/locations/united-states/library/insight-brief/ten-medtech-trends-to-watch-in-2025Host: Michaela Miller, Practice Lead, U.S. MedTech Technology & Analytics, IQVIAFeatured Speaker: Michelle Edwards, Practice Lead, U.S. MedTech Real World and Clinical Solutions, IQVIA

Join us for "Breaking Down Site Complexities and Start-Up Barriers in Clinical Trials" as we uncover the complexities of site management and the barriers to effective study start-ups. Discover the top issues impacting research sites and strategies to overcome them, including trial complexity, start-up hurdles, and long initiation timelines.  Learn how effective communication, teamwork, and clear processes can drive success, and the importance of human connections and inclusivity in clinical research. Get practical advice for improving site readiness and trial efficiency from our expert guests.  Don't miss this essential episode on navigating the evolving clinical trial landscape at sites. Guests:Jessica Thurmond, program director, WCG Pat Harrington, senior vice president, Clinical Solutions & Strategic Partnering, WCG Brad Gruener, vice president, Site Services, WCG 

Dr. Eva Luo, OB/GYN and Head of Clinical Solutions at Pomelo Care, joins Kellogg MBA student Kaiya Adam to discuss how Pomelo Care is tackling the maternal health crisis in the U.S. with a compassionate and evidence-based care model.  Visit our podcast page for more episodes on trends and innovation in healthcare and follow our socials so you never miss an update.  LinkedIn Timestamps: (2:04) - Meet Dr. Eva Luo (7:45) - Assessing the current state of maternal health in the U.S. (8:55) - Exploring Pomelo Care's 24/7 virtual and in-person service offerings (19:35) - Understanding Pomelo Care's compassionate, evidence-based model (28:49) - Measuring the positive impact of Pomelo Care's model on clinical outcomes (30:46) - Pioneering value-based innovations in maternal health 

In this episode of "WCG Talks Trials," host Geoffrey Schick, director of strategic site partnerships, WCG, is joined by fellow MAGI@home 2024 speakers Sandy Smith, Jess Thompson, and Wesley Warren. They share their unique perspectives and key takeaways from this year's virtual conference, including discussions on contract negotiations, the evolving role of advanced practice practitioners, and the collaborative panels featuring both site and sponsor/CRO insights. The episode also recaps the impactful session on the FDA's Diversity Action Plan and what it means for the future of clinical trials. Tune in to hear about the dynamic energy, valuable connections, and innovative challenges that make MAGI and MAGI@home standout events in clinical research. Don't miss out on the exciting plans for MAGI 2025 in Boston, where trends will continue to evolve and new opportunities will emerge. Guests: Geoffrey Schick, MBA, CHRC, Director of Strategic Site Partnerships, WCG  Sandy Smith, RN, MSN, AOCN, Senior Vice President, Clinical Solutions & Strategic Partnerships, WCG Jess Thompson, MS, MBA, PMP, Founder, ACRPM.org Wesley Warren, J.D., Executive Director, Research Strategy & Partnerships, City of Hope 

Hosts James Benham & Rob Galbraith are joined by Greg Nichols from SPNet Clinical Solutions. Greg joins the podcast to dive on how technology helps drive better rehabilitation outcomes for injured workers. Learn how data-driven approaches and innovative service models are transforming the delivery of physical medicine and improving efficiency.  This Episode is sponsored by JBKnowledge, Technology Solutions for Insurance & Risk Management. Find us on social media! We're on LinkedIn, Twitter, and Instagram; or follow James on Twitter!  Subscribe, rate, and comment. As always, Enjoy the Ride & Geek Out!

In this episode, Nursing Economic$ Editorial Board Member Dr. Rhonda Anderson talks with Dr. Danyel Germain, the Vice President of Customer Success and Clinical Solutions for Elsevier, Dr. David Berger, the CEO of SUNY Downstate Medical Center, and Krishnan Gopalakrishnan, Co-founder and CEO of Plannery. They discuss the financial challenges nurses face, from student loans and credit card debt to inflation, and how these pressures impact nurse retention and patient care. The conversation also highlights innovative solutions like Plannery, which aims to help health care workers manage their debt and improve their overall financial wellness.Danyel Germain, DNP, RN, CHSE, is the Vice President of Customer Success and Clinical Solutions for Elsevier in Philadelphia, Pennsylvania.David Berger, MD, MHCM, FACS, is the CEO of SUNY Downstate Medical Center in Brooklyn, New York.Krishnan Gopalakrishnan, MBA, is Co-founder and CEO of Plannery in San Mateo, California. Rhonda Anderson, DNSc(h), MPA, BS, RN, FAAN, LFACHE, is a Health Care Consultant for RMA Consulting in Phoenix, Arizona, and an Editorial Board Member of Nursing Economic$.© Jannetti Publications, Inc.All rights reserved. No portion of this podcast may be used without written permission.To learn more about Nursing Economic$, visit http://www.nursingeconomics.net Visit our new JPI journal platform at www.jannettipublications.comMusical selections by Scott Holmes.http://www.scottholmesmusic.com

In this special episode, we are on the road in New York City at our 21st annual Specialty Summit. More than 600 people have come to Times Square to listen to exceptional speakers, gain insight from insightful expert panels and network with the brightest minds in specialty. In this segment, you'll hear from Prime's Senior Vice President, Specialty and Clinical Solutions, about why high-cost specialty drugs continue to dominate the pipeline. You'll learn how Prime is making it easy for patients to access the specialty medicines they need, a simplified approach to a complex problem where we support patients in their journey. As a bonus, Steve also talks about how Prime's new brand represents our ambition to become an icon for change and innovation in pharmacy solutions. Get insights into how Prime is reshaping pharmacy benefits management in a way that is patient centric, more affordable and more intuitive.

In this special episode, we are on the road in New York City at our 21st annual Specialty Summit. More than 600 people have come to Times Square to listen to exceptional speakers, gain insight from insightful expert panels and network with the brightest minds in specialty. Today, we're talking with several leaders at Prime about how each is focusing their work on the three pieces of our newly formed framework. We want to help make medications more affordable, deliver an easy, transparent experience and, most importantly, help people achieve better health. Pt. 1 – The specialty pharmacy shift – Reimagining for success In this segment, you'll hear from Prime's Senior Vice President, Specialty and Clinical Solutions, about why high-cost specialty drugs continue to dominate the pipeline. You'll learn how Prime is making it easy for patients to access the specialty medicines they need, a simplified approach to a complex problem where we support patients in their journey. As a bonus, Steve also talks about how Prime's new brand represents our ambition to become an icon for change and innovation in pharmacy solutions. Get insights into how Prime is reshaping pharmacy benefits management in a way that is patient centric, more affordable and more intuitive. Pt. 2 – Cell & gene therapy – The crossroads of sci-fi and reality The frontier of medicine is here, and we're talking about cell and gene therapy. In this segment, VP of Clinical Strategy and Programs, Jim Rebello, discusses how medicines are causing a seismic shift and rewriting the way we treat conditions and the code to life itself. But these innovations bring a heavy price tag, so we dive into what Prime is doing to navigate this space. Pt. 3 – Health tech horizons – Diverse voices, unified innovation In this segment, Chief Information Officer, Dinesh Kandanchatha, dives into how technology plays a role in accelerating innovation to meet the moment for our customers. You'll hear about his interview with Bill Nye the Science Guy from their closing keynote session from our Specialty Summit, where attendees heard about the developments in artificial intelligence and its potential impact on the health care industry and beyond.

In this episode, IQVIA's Raj Stewart and Michelle Edwards dig deeper into IQVIA's annual “Ten MedTech Trends to Watch” report, which focuses on the key trends impacting the U.S. MedTech industry today. Learn how health equity, the consolidation of health systems, and advances in diagnostics are impacting the need for evidence generation among MedTech manufacturers and suppliers.Read Ten MedTech Trends to Watch in 2024 to learn more. Host: Michaela Miller, Practice Lead, U.S. MedTech Technology & Analytics, IQVIAFeatured Speakers: Michelle Edwards, Practice Lead, U.S. MedTech Real World and Clinical Solutions, IQVIARaj Stewart, Principal, MedTech Market Access, IQVIA

In this episode, Tina Ličková talks with Dr. Breanna Gentile about integrating psychological principles into UX design, focusing on trauma-informed practices. They explore how understanding users' emotional and psychological backgrounds can inform better design decisions. Dr. Gentile emphasizes cultural sensitivity, the blend of qualitative and quantitative research methods, and the importance of creating safe digital environments. The conversation shows how recognizing the human side of user experiences leads to more empathetic and effective UX research.

How can product leaders cultivate impactful products? In this episode of the Product Leaders to Watch series with Cognizant Product Director Chenny Solaiyappan, MEDFAR Clinical Solutions Product VP Patrick Charbonneau shares insights from 20 years of experience across industries including healthcare, security, and retail. The conversation covers key tech trends such as AI and how it can be applied in healthcare to improve patient and physician experiences. They also explore what makes a great product manager through listening skills and understanding customer needs, as well as what qualities define a great product, such as creative problem-solving and customer adoption.

Lora Sparkman, an RN and VP and Partner of Clinical Solutions, Patient Safety, and Quality at Relias, highlights the high maternal mortality rate in the US and the factors that contribute to it.  Lora emphasizes the need for standardization of definitions and a better understanding of the social determinants of health that influence the success of a pregnancy, including the need for pre-pregnancy and post-pregnancy healthcare. Digital technology is bringing advancements to healthcare education and helping overcome geographic barriers to improve outcomes and reduce maternal morbidity and mortality. Lora explains, "In some cases, we're getting our hands around the real story versus some variation across states and definitions, and how death was categorized, those types of things. Putting that all behind us, there's been a lot more work and effort at the federal and national levels to standardize definitions and categories."   "There's been kind of a shift we've seen over the last couple of years, which is we've been very focused on the death rate, again, but that's kind of like, what's leading up to that? Why are we having so many deaths? We're starting to understand and see that we need to focus on pre-pregnancy health, general health, and access to healthcare during pregnancy. Severe maternal morbidity affects about 50,000 to 60,000 women each year. Those numbers are growing." "No matter where pregnant people are getting their care, our aim and the work that we've been doing at Relias is focused on standardization of using care delivery and protocols and making sure that physicians, nurses, midwives, or anyone who is caring for pregnant people, are utilizing evidence-based guidelines, are aware of the latest evidence-based in research in areas like hypertension, and obstetric hemorrhage, and substance use disorder in pregnancy." #Relias #Nurses #MaternalMortality #MaternalMorbidity #Pregnancy #WomensHealth #ClinicalTraining #SDOH Relias.com Download the transcript here

Lora Sparkman, an RN and VP and Partner of Clinical Solutions, Patient Safety, and Quality at Relias, highlights the high maternal mortality rate in the US and the factors that contribute to it.  Lora emphasizes the need for standardization of definitions and a better understanding of the social determinants of health that influence the success of a pregnancy, including the need for pre-pregnancy and post-pregnancy healthcare. Digital technology is bringing advancements to healthcare education and helping overcome geographic barriers to improve outcomes and reduce maternal morbidity and mortality. Lora explains, "In some cases, we're getting our hands around the real story versus some variation across states and definitions, and how death was categorized, those types of things. Putting that all behind us, there's been a lot more work and effort at the federal and national levels to standardize definitions and categories."   "There's been kind of a shift we've seen over the last couple of years, which is we've been very focused on the death rate, again, but that's kind of like, what's leading up to that? Why are we having so many deaths? We're starting to understand and see that we need to focus on pre-pregnancy health, general health, and access to healthcare during pregnancy. Severe maternal morbidity affects about 50,000 to 60,000 women each year. Those numbers are growing." "No matter where pregnant people are getting their care, our aim and the work that we've been doing at Relias is focused on standardization of using care delivery and protocols and making sure that physicians, nurses, midwives, or anyone who is caring for pregnant people, are utilizing evidence-based guidelines, are aware of the latest evidence-based in research in areas like hypertension, and obstetric hemorrhage, and substance use disorder in pregnancy." #Relias #Nurses #MaternalMortality #MaternalMorbidity #Pregnancy #WomensHealth #ClinicalTraining #SDOH Relias.com Listen to the podcast here

Is it possible to implement solutions that benefit both patients and clinicians? At the HLTH 2023 conference, this was the exact question we asked Patches Seely, MBA, BSN, RN, EVP of Clinical Solutions at Carenet Health. Seely and Carenet Health have an interesting perspective on this topic since their goal is to “Modernize Healthcare Engagement.” Carenet Health works to do this for health plans, providers, and even employers. Plus, Seely is bringing a unique clinical perspective to their products as a nurse herself. Check out our interview with Patches Seely from Carenet Health to learn more about how the right engagement solutions can benefit both patients and clinicians. Learn more about Carenet Health: https://carenethealthcare.com/ Healthcare Marketing Community: https://swaay.health/

In this episode, Tammy Cress, RN, BSN, Vice President of Clinical Solutions and Innovation at Teladoc Health discusses why virtual nursing is among the fastest-growing segments of virtual care, opportunities for broader positive impact within an organization, and how health systems are already experiencing success by leveraging this innovative approach.This episode is sponsored by Teladoc Health.

Kristen Carnahan's unique path to becoming a clinician will inspire you as she shares her journey of moving from clinical practice to academia and back into private practice. We talk through the critical principles of lower limb prosthetic alignment.  Kristen also touches on her specialty, active vacuum suspension systems, which have evolved significantly over the last two decades.  Bringing this episode to a close, we look to the future exploring the potential of 3D printing, scanning in practice, and their promise. 

In the first episode of our new podcast series, WCG Talks Trials, we are joined by three industry experts, Lisa Ballance from Virginia Commonwealth University, John Musser from Florida Cancer Specialists and Research Institute, and Dan Otap from Genentech, to discuss the topic of overcoming site challenges and addressing site burden.Listen in as we discuss the results of WCG's recently published 2023 Clinical Research Site Challenges Survey Report, gain insights from our guests on solutions their organizations have implemented to reduce site burden, and share perspectives on how sites, sponsors, and CROs can work to improve site and trial efficiency. Speakers: Sandy Smith, RN, MSN, AOCN  Senior Vice President, Clinical Solutions and Strategic Partnerships at WCG ClinicalLisa Richman Balance Associate Vice President for Research Strategy and Regulatory Affairs at Virginia Commonwealth University John Musser Senior Director, Clinical Research Administration at Florida Cancer Specialists & Research InstituteDan Otap Principal, Alliance and Partnerships Lead at Genentech

May 16: Walk the floor with This Week Health. Check out the booths you may have missed at the spring health IT conferences. In this episode we feature:Travis Bias, Chief Medical Officer, Clinical Solutions at 3M Rich Birhanzel, Senior Managing Director at AccentureJason Knox, Solutions Manager, Enterprise Imaging at AGFA HealthCareJason Bevis, Cybersecuirty professional services at Arista NetworksJoin us on June 8 at 1PM ET for our webinar: 'The Future of Care Spaces' This webinar will focus on the latest healthcare technologies and solutions transforming care spaces in America. Care spaces can include hospitals, clinics, and at-home treatments where advanced technologies can enable better workflows, treatments, and patient outcomes. Register Here: https://thisweekhealth.com/future-of-care-spaces/Subscribe: This Week HealthTwitter: This Week HealthLinkedIn: Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

In this episode we are joined by Susan Pasley, MS, BSN, RN, Vice President of Clinical Solutions at CareRev, to discuss the current state of the nursing workforce, where to start with relieving nurse staffing challenges, the benefits of having experienced nurses on demand and more.This episode is sponsored by CareRev.

In this week's episode of health care trailblazers, our guest Greg Burrell shares his thoughts on how he co-founded Carbon Health, the challenges he and his team faced, the pros and cons of partnering with venture capitalists, and why he ultimately decided to take a step back from his role at Carbon Health. About GregGreg Burrell, MD is a physician executive and a product and operations leader. He is currently the Chief Medical Officer at Gravie, a groundbreaking new way for employees to get medical benefits and care. Previously he was the Vice-President of Clinical Solutions and Associate Chief Medical Officer at Accolade (Nasdaq: ACCD). He was also the Co-Founder and Vice President of Clinical Product & Strategy at Carbon Health, an innovative primary care system integrating in-house advanced technology with coordinated delivery in order to provide a highly efficient, improved quality of care without increasing cost. A board-certified internist, Greg completed his medical training at the University of Chicago and his residency at the University of California San Francisco. where he served for many years as an Associate Professor of Clinical Medicine. He continues to practice as an internal medicine physician.Learn more about Greg BurrellLinkedIn: https://www.linkedin.com/in/gregburrell/ Learn more about Previva Health Group:Website: https://previva.com/ LinkedIn: https://www.linkedin.com/company/previva-health-group/

Dr. Jason Cohen, Senior Director of Clinical Solutions at Qventus, is addressing the problems that hospitals face regarding discharging patients. Much of care planning starts during hospitalization or at the last minute, so patients and caregivers are often left confused about the next appropriate care environment. Qventus is deploying AI to build a model with hundreds of different data points to predict highly-individualized discharge plans. This benefits patients, hospitals, and care teams by keeping track of progress, identifying bottlenecks, and making necessary adjustments to the care plan. Jason elaborates, "We look at patients, for example, who get an early discharge plan, which we define as being an estimated date of discharge and a disposition where they're likely to go. Those patients that have their care team aligned around that early plan by the second midnight in the hospital experience have significantly fewer excess days in the hospital. They're more likely to leave on time and get to their next most appropriate care environment, whether that's a skilled facility, rehab, home with home help, et cetera. And then on the other side of that, again, is that tension with the dynamically changing nature of that patient's health, and things can change from day to day." "Our solution has multiple different components, which hopefully we'll get into, but one of the core parts is our AI machine learning model that is able to help care teams align on that early discharge plan as soon as possible. And in the case of our models, the majority of patients, we're able to populate that plan directly into the EHR so that there's transparency across all those teams after the first midnight in the hospital." @Qventus #Qventus #HospitalDischargePlanning #HospitalDischarge #AI #BigData #Hospitals Qventus.com Listen to the podcast here

Dr. Jason Cohen, Senior Director of Clinical Solutions at Qventus, is addressing the problems that hospitals face regarding discharging patients. Much of care planning starts during hospitalization or at the last minute, so patients and caregivers are often left confused about the next appropriate care environment. Qventus is deploying AI to build a model with hundreds of different data points to predict highly-individualized discharge plans. This benefits patients, hospitals, and care teams by keeping track of progress, identifying bottlenecks, and making necessary adjustments to the care plan. Jason elaborates, "We look at patients, for example, who get an early discharge plan, which we define as being an estimated date of discharge and a disposition where they're likely to go. Those patients that have their care team aligned around that early plan by the second midnight in the hospital experience have significantly fewer excess days in the hospital. They're more likely to leave on time and get to their next most appropriate care environment, whether that's a skilled facility, rehab, home with home help, et cetera. And then on the other side of that, again, is that tension with the dynamically changing nature of that patient's health, and things can change from day to day." "Our solution has multiple different components, which hopefully we'll get into, but one of the core parts is our AI machine learning model that is able to help care teams align on that early discharge plan as soon as possible. And in the case of our models, the majority of patients, we're able to populate that plan directly into the EHR so that there's transparency across all those teams after the first midnight in the hospital." @Qventus #Qventus #HospitalDischargePlanning #HospitalDischarge #Hospitals #AI #BigData Qventus.com Download the transcript here

Hear from Employers Health's Vice President of Clinical Solutions, Matt Harman, as he shares the clinical team's learnings at the Academy of Managed Care Pharmacy Nexus conference, what the team's growth means for Employers Health clients, upcoming clinical strategies for self-insured employers and more. 

In this episode we hear from Lauren Goston, RN, and Susan Pasley, the VP of Clinical Solutions at CareRev. Tune into their conversation to learn how CareRev is offering a technology solution that is changing the future of work in healthcare and more.This episode is sponsored by CareRev

“But I've got block time!” insisted the surgeon. “I'm sorry, but your block time was released yesterday and another surgeon has now posted cases in that spot,” said the OR scheduler…. Sound familiar? We seem to have conversations like this frequently. How can we make sure that our policies around block time are well-defined and understood by everyone? How can correct block utilization affect productivity and efficiency? Learn all about block scheduling today as we talk with Shawn Sefton, MBA, BSN, RN, Chief Nursing Officer and Vice President of Clinical Solutions at Hospital IQ. We'll discuss the importance of establishing block utilization policies and the best ways to track block utilization. Don't miss this exciting Season 4 finale!! Love our show? Download our First Case mobile app on:

What are the most important lessons learned by clinical research sites from having to deal with the COVID-19 pandemic the last two years, and what are the challenges these sites face going forward?. That's the key topic explored during Senior Advisor Linda Sullivan's interview with Sandys Smith, Senior Vice President, Clinical Solutions and Strategic Partnerships for WCG. Smith, who has spent her career partnering with physicians and other healthcare stakeholders to drive customer value and clinical excellence in patient-centric oncology services, discusses how the lockdown affected clinical research site operations, and what enabled certain sites to pivot more easily. Smith discusses how telehealth and remote monitoring took off, hospitals functioned with insufficient staff, and the Great Resignation occurred. What that meant, she says, was that fewer personnel and resources were available to health care organizations and clinical sites. Smith also talks about where clinical sites are today in terms of trial backlogs, a recent uptick in new starts in March, still existing staffing shortages and the need for additional training for less experienced investigators, and how sites can be better supported. Finally, Smith talks about the advantages of adopting a hybrid, decentralized clinical trial model — a combination of onsite and virtual participant visits — that enables sites to enroll patients who don't live near clinical sites. Clinical sites are looking at how to get the work done most effectively, such as partnering with outside organizations to do budgets and/or utilizing remote staffers and deploying technology-based research solutions, according to Smith.

Please subscribe to our youtube page to get notices on all new podcasts as well helping us grow our audience. https://www.youtube.com/c/NewClevelandRadioMelinda and Roberta talk about Clinical SolutionsBefore starting her own consulting firm, Roberta Brofman's nursing career encompassed a wide variety of healthcare experience -- both in Clinical Practice and Operations -- in Skilled Care, Long-Term Care, Critical Care, Homecare, Hospice and Acute Care, including:• As the Director of Nursing for a skilled nursing facility, Roberta developed clinical programming in heart failure which led to a reduction in returns to acute care, an increase in hospital referrals and increased revenue. Her leadership development and Quality Assessment Performance Improvement (QAPI) skills in fall and wound prevention provided additional positive results.• Under her leadership as the Director of Nursing and Program Development for a 63-bed skilled post-hospital nursing unit, the facility achieved three years of deficiency-free, Ohio Department of Health (ODH) surveys and a perfect Five-Star rating from the Center for Medicare and Medicaid Services (CMS).• During her 13 years of homecare experience, Roberta served as a direct care manager and clinical coordinator of over 200 skilled, passport and private duty patients. Under her management, the department achieved perfect surveys from the Ohio Department of Health, the Joint Commission and Passport Services and was designated as HomeCare Elite Top 25% in the nation.• Roberta's experience as a Director of Quality includes the establishment of deemed status by the Joint Commission (JCAHO) of a newly opened Inpatient Rehab Facility (IRF) where she then led the facility as Chief Nursing Officer.• As the Chief of Strategic Planning and Program Development at the Visiting Nurse Association of Ohio, Roberta was responsible for the development of successful programs in Heart Failure, COPD/Pneumonia and Orthopedics along with an automated data reporting structure for outcome measures in all clinical areas. Now, as the President and Founder of Five Star Clinical Solutions, Roberta works with organizations on both the clinical and operations side to evaluate where process improvements can be made to enhance outcomes and increase referrals. Her programs deliver measurable outcomes in staff and patient satisfaction, leadership, programming, certification and survey results.https://fivestarclinical.com/For more information or to listen to Heart Mojo Podcasts go to: https://newclevelandradio.net/listening-links/heart-mojo-with-melinda-smith/

Healthcare is an evolving system that has gone through many changes and will continue advancing over time. In this episode, we hear from Dr. Tate Erlinger, the Vice President of Clinical Analytics at Elsevier Clinical Solutions, about the advantages and challenges of the Clinician of the Future and Elsevier's recent report, which points out possible obstacles and suggests improvements to the industry. The relationship between patient and doctor is at the core of healthcare. Dr. Erlinger says that technology has changed the relationship's nature and should be nurtured to keep on improving it. Accessibility through Telehealth, on-demand information, and payment for quality have been identified as challenges or advantages that need to be addressed. He believes this shouldn't discourage the clinicians of the future, as they can participate in the resolution of those challenges and be rewarded with being able to help more people directly. Tune in to this episode to listen about his hopes, work, and thoughts regarding the future of healthcare! Click this link to the show notes, transcript, and resources: outcomesrocket.health

Have you struggled getting out there and getting more work from dental offices? Not every lab has the resources from a sales team, but you can learn a lot from a lab that does. Lauren Crowe came to Blue Box Dental Lab (https://www.blueboxdental.com/) with a lot of clinical experience. Always working hard, Lauren worked her way up to manager and eventually became the Director of Sales for Leixir (https://www.leixir.com/) (a group of 5 labs). Lauren talks getting lab sales, struggles of selling to dentists, selling to DSOs, and how with a team of 13 salespeople, training and providing services and not products. There are 3D Print resins for models that do a decent job, then there is Whip Mix (https://www.whipmix.com/) VeriModel OS. Dr. Michael Scherer, a prosthodontist from Sonora, CA says “Whip Mix VeriModel OS is one of the finest model resins I have ever worked with. It's amazing”. The popular resins offer the dental laboratory a high quality, smooth surface finish, extreme precision, reliable accuracy, and fine detail. They can be used in 385 and 405 nanometer printers, and are compatible with silicone-base separators. VeriModel OS print resins are available in Ivory (https://www.whipmix.com/products/verimodel-os-ivory-dental-resin/), Golden Brown (https://www.whipmix.com/products/verimodel-os-golden-brown-dental-resin/), Grey (https://www.whipmix.com/products/verimodel-os-grey-dental-resin/), and White (https://www.whipmix.com/products/verimodel-os-white-dental-resin/) colors for any model application. For more information, call (800) 626-5651, or visit www.whipmix.com. Did you know that most inLab MCX5 users that have ordered burs from Gro3X once, keep on ordering Gro3X burs over and over again? Because Gro3X (https://www.gro3x.com/) burs are engineered by some of the folks who have been providing burs to some of the largest US production labs for years. Did you also know, that most Roland and DGShape users have no idea what they are missing out? To give Roland and DGSHAPE users the opportunity to find out for themselves how good Gro3X burs work also for their machines, Gro3X is now offering a BUY 3, GET 2 BURS FREE special. This is exclusively for Voices From The Bench listeners. Simply go to the Gro3X website at gro3x.com (https://www.gro3x.com/) click on burs (https://www.gro3x.com/collections/mill), then select Roland & DGSHAPE. Add five burs of your choice to your cart, click on CHECK-OUT, enter discount code B3G2Burs and check out. Is your lab in a position to take on new customers? Do you have the capacity to service more doctors? AmericaSmiles (https://americasmiles.net/) has helped hundreds of labs across the country to acquire new dental accounts.They're the biggest name in Dental Laboratory marketing. Don't waste time mailing and calling hundreds of doctors just to see poor results and hear overwhelming rejection. Let AmericaSmiles do all the heavy lifting for you. For just $195 a month, the AmericaSmiles One Voice program will help you skip to the front of the line. They'll prospect your local or target area, produce your creative marketing, and do all of the cold calling to leave you with extremely qualified appointments; guaranteed to help you find your ideal clients and grow your business. Visit AmericaSmiles.net/One-Voice to learn more about how you can increase your lab's bottom line. Use promo code VOICESFROMTHEBENCH during checkout to qualify for a month-to-month agreement enabling you the freedom to cancel the marketing service any time! If you'd like to speak with an agent who can answer your questions about a time-tested, completely done-for-you approach to marketing, please call 708 279 9031. Join AmericaSmiles One Voice today - Getting new dentists to try your lab has never been easier. Special Guest: Lauren Crowe.

Despite being a self-described “data geek” Josh Schoeller is well aware of the challenges in making sense of the ever-expanding amount of healthcare-related data. As he puts it, “More data doesn't necessarily mean more knowledge.” As president of Global Clinical Solutions at Elsevier and CEO of Healthcare for LexisNexis Risk Solutions, Schoeller is in a unique position to see how all of this data can be leveraged in better ways to support learners, practitioners, patients and the healthcare system at large. “On the LexisNexis side, we have a mission to create healthier communities and on the Elsevier side, it's to improve every patient outcome. So, they're very much aligned and are both mission-driven organizations built around people that are very committed to using data and analytics and content to help improve healthcare in the U.S. and throughout the world.” Check out this penetrating discussion with host Shiv Gaglani as he draws out valuable insights from Schoeller on the current and future role of data in clinical decision-making, patient privacy, health equity, the efficiency of healthcare delivery, and much more.

Charles Moore of Censuswide surveys, and Teri Ridge, Hospital IQ's Director, Clinical Solutions, discuss the results of Hospital IQ's survey of 200 hospital-based nurses and what their overwhelming desire to leave the bedside means for health systems in 2022.

277. Kitcheck Bluesight Insights and Data Integration feat. Dr. AJ Rivosecchi Intended Audience: Everyone How does the future of data integration look like for the pharmacy profession? On today's episode, originally recorded in early 2021, we had the opportunity to speak with Dr. AJ Rivosecchi, Product Manager and Director of Clinical Solutions at Kitcheck. Dr. Rivosecchi shares his expertise discussion the vision of Kitcheck's medication future and the importance of data being accessible and actionable for operational practices. On today's episode: Dr. Rivosecchi shares his journey from pharmacist to product manager He shares the vision and goals that Kitcheck is striving towards He discusses the Kitcheck Bluesight Insights product and its purpose and benefits He provides advice on those looking to position themselves into healthcare technology To learn more about Kitcheck, visit https://www.kitcheck.com To contact Dr. Rivosecchi, you can reach him at https://www.linkedin.com/in/alex-rivosecchi-15581914a/ Opinions in the podcast represent that of the individual and not the employer. ========== Interested in learning more about pharmacy informatics? Check out the FREE Introduction to Pharmacy Informatics course at www.pharmacyinformaticsacademy.com ! New to LinkedIn and not sure where to start? Download my free ebook, "Professional Networking Unlocked", at https://www.tonydaopharmd.com/ebook Follow us on social media! Twitter: @pharmacyitme Instagram: @pharmacyinformatics LinkedIn: https://www.linkedin.com/company/pharmacyitme/ Website: Pharmacy IT & Me Email: tony@pharmacyitme.com Follow Tony's personal Twitter account at @tonydaopharmd Network with other pharmacists at Pharmacists Connect!http://pharmacistsconnect.com For more information on pharmacy informatics, check out some of the following useful links: ASHP's Section of Pharmacy Informatics and Technology: https://www.ashp.org/Pharmacy-Informaticist/Section-of-Pharmacy-Informatics-and-Technology/ HIMSS Pharmacy Informatics Community: https://www.himss.org/library/pharmacy-informatics Disclaimer: Views expressed are my own and do not reflect thoughts and opinions of any entity with which I have been, am now, or will be affiliated.

Dr. Ed Cohen is the Executive Vice President of Pharmacy Advocacy for MJH Life Sciences, the largest, privately held healthcare media business in North America. He works on behalf of pharmacies and pharmacists to bring them information and ideas that can enhance their practice and impact their patient care services. Prior to this, Dr. Cohen served as the Senior Director of Clinical Solutions for Walgreens and as the Director of Pharmacy Operations for Safeway Corporation. In addition to his corporate experiences, he has held several faculty positions and earned numerous professional certifications and industry awards. Dr. Cohen has also made major contributions to the content direction of Pharmacy Times magazine as a member of its Editorial Board. He holds a Doctor of Pharmacy degree from Midwestern University and a Bachelor's Degree from the University of Illinois at Chicago. Connect with Dr. Cohen today at https://www.linkedin.com/in/ed-cohen-pharmd-fapha-9385016/ Are you a healthcare professional or healthcare executive looking to advance your career, build a better brand, or create a leadership legacy? Iqbal can help! Schedule your FREE CONSULTATION today at https://atchainternational.com Connect with Iqbal on: - Linked at https://www.linkedin.com/in/iqbalatcha/ - Instagram at https://www.instagram.com/iqbalatcha1 - Twitter at https://twitter.com/IqbalAtcha1 Join us next week for another exciting episode of the "Healthcare and Higher" podcast! #HealthcareAndHigher #IqbalsInterviews Song Credits: "Life Is A Dream" by Michael Ramir C. "Stay With Me" by Michael Ramir C. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/iqbal-atcha/support

Sandy Smith, Senior Vice President of Clinical Solutions and Strategic Partnering at WCG Clinical and SCRS Global Oncology Summit Chair shares what she is most excited about for this year's Oncology Summit, including some of the hot topics we will cover at the Summit. Learn what attendees can expect from the Summit and how to maximize your experience!Learn more about the Global Oncology Summit and register today at https://oncologysitesolutionssummit.com/

In this episode of AFSPA Talks, COO Kyle Longton discusses staying healthy throughout the holiday season with Dr. Jonathan Rubens, Chief Medical Officer of ActiveHealth Management. Senior Director Leah Briggs also joins the conversation to give us more information on Lifestyle and Condition Coaching and how a coach can help you stay on track this holiday season. Jonathan S. Rubens brings more than 25 years of experience as a physician leader in both academic and community settings. As the CMO, Jonathan leads a multidisciplinary team of physicians, pharmacists and nurses focused on building effective population health management programs and clinical analytic tools to promote evidence-based patient care.Leah Briggs is Senior Director of Clinical Solutions at ActiveHealth and a Registered Nurse with over 13 years of case management experience. Along with Dr. Rubens, Leah leads the strategic evolution of clinical programs at ActiveHealth Management, including the Lifestyle and Condition Coaching program.For more information on the Lifestyle and Condition Coaching program, click here. 

Dan Meltzer, MD is a board-certified emergency physician, the former chief and chairman of the Department of Emergency Medicine at Kaiser Permanente in San Diego, and has had executive leadership roles as CMO for several organizations, and is currently the Chief Medical Officer of Clinical Solutions for Matrix Medical Network. Dan is a wealth of knowledge, and shares great perspectives from a life filled with rich experiences. https://www.linkedin.com/in/daniel-meltzer-md-mph-facep-b789a2b6/# https://matrixmedicalnetwork.com/ SPECIAL THANKS: https://www.Fewwillhunt.com - Everyone wants to Eat... Few Will Hunt. "JBP" = 15% Off https://www.fellowshipbrand.com - Premium Men's Grooming Products "JBP" = 10% Off https://www.Stream2sea.com - All Natural Care Products and Sunscreen "JBP" = 10% Off

On this episode of HR Benecast we are joined by Mark Bolton, senior director of public policy and senior legal counsel at Greenwich Biosciences and Employers Health's Vice President of Clinical Solutions, Matt Harman.  Together, they share the findings of a recent employer roundtable on cannabis in the workplace. They'll cover employers' top concerns regarding coverage of cannabis under the employee benefit plan, the process of taking a cannabis drug through the FDA approval process, what employers should be thinking about when it comes to cannabis and medical marijuana policies, the future of the drug and employee benefits policies and more. 

Ron Rerko, head of clinical solutions at Soteria Precision Medicine Foundation and executive director of genomics at Family Care Path. With over 20 years of experience in cancer research—and 13 years at the Cleveland Clinic as director of genomics in the Genomic Medicine Institute—Ron has developed and implemented programs in medical genetics, genomic medicine, pharmacogenomics, and telehealth, as well as extensive business development efforts.

In this episode, Kim and I discuss the diagnostic market, where it is going, personalized medicine, and more. Kim Gilonske LinkedIn Duane Mancini LinkedIn

Crystal Dugger, VP of Clinical Solutions, sits down with two members of our self-proclaimed “COVID-Squad”, Karen Bush and Sarah Michel. The squad was formulated in an effort to provide our members with streamlined guidance and resources to navigate the rapidly changing landscape that is COVID-19. During the height of the pandemic, the team published 5-10 documents on a weekly basis. This is a conversation about the organizational structure needed to create the research documents, PPE Conservation, and the passion needed to keep our communities safe.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

The COVID-19 pandemic is impacting clinical trials in many ways, not the least of which being the ability for sponsors to continue traditional oversight activities such as on-site clinical trial monitoring. The Association of Clinical Research Organizations (ACRO) has issued recommendations for clinical trial monitoring that will help maintain continuity in clinical trials wherever possible.In this episode in our Coronavirus Special Edition Series, Paul Colvin, President, Clinical Solutions and Nicole Stansbury, Vice President, Global Clinical Monitoring at Syneos Health, discuss the role of risk-based monitoring and  opportunities for remote options that can potentially ensure continuity, trial viability and data preservation through this pandemic and beyond.Read more about remote risk-based monitoring in action in this Clinical Leader article, and be sure to watch our webinar on implementing remote clinical trial monitoring.Stay tuned for more installments of the Coronavirus Special Edition Series, which will explore, from an operational standpoint, the impact of COVID-19 on the biopharma industry, the challenges for rapid R&D in an outbreak environment, and the opportunities to leverage technology and innovation to address these critical issues. Additional materials and insights can also be found in our COVID-19 Resource Center.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you're hearing?  Be sure to rate and review us!  We want to hear from you!  If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com. * This episode was recorded on 3/26/2020.

This interview is part of our HIMSS18 coverage. We'll be talking with thought leaders and vendors all week at the annual Health Information Management Society conference in Las Vegas. On this episode we talk with Travis Moore, SVP of Market Solutions at Kyruus and Matt Gove, Chief Consumer Officer at Piedmont Healthcare, about provider data and patient access. We discuss how to address provider data inconsistencies across systems so that you can enable a better patient experience. Topics include: Self-scheduling and why your patients are ready for it Call-center scheduling Doctor-to-doctor referrals and in-office scheduling Why at Piedmont Quick Care Retail Clinics in Walgreens more than 50% of the volume is booked online. The big take away for me is that patients are ready for online scheduling and they want to be seen on their own terms. This is evident in Piedmont's high online booking rates, a preference to have a scheduled time even at walk-in retail clinics and in how millennials seem to be embracing asynchronous telemedicine options. About Travis Moore, SVP of Market Solutions at Kyruus Travis Moore is Senior Vice President of Market Solutions at Kyruus, where he is responsible for working with existing, and future clients, to provide them with insight into how the Kyruus platform can be used to improve patient access. Prior to joining Kyruus, Travis was with Influence Health for 12 years – starting his career as a Sales Account Executive, then transitioning into the Director of Sales role, and later becoming the VP of their Sales / Product Specialty team. Additionally at Influence Health, Travis was VP of Product Management and Strategy before eventually focusing on the clinical aspects of the business as the SVP of Clinical Solutions and Sales. Prior to Influence Health, Travis was responsible for Product Management over the patient education and nursing solutions at Truven. Travis started his career in healthcare as a Pediatric Nurse on the Neurotrauma and Orthopedic unit at Children's Hospital in Denver, CO. Travis has his Bachelor's degree in Nursing from University of Wisconsin-Milwaukee and MBA from University of Phoenix-Denver. Twitter: https://twitter.com/tmoore634RN LinkedIn: https://www.linkedin.com/in/travis-moore-mba-rn-4651b11/ About Matt Gove, Chief Consumer Officer at Piedmont Healthcare Matt Gove is Chief Consumer Officer for Atlanta-based Piedmont Healthcare, where he oversees marketing, communications, patient experience, community benefit and government relations for the seven-hospital system. As Piedmont's Chief Consumer Officer, Matt shapes the system's approach to healthcare consumerism, working closely with physician practices, hospitals and outpatient services to provide a better understanding of Piedmont's customers, how to better meet the consumer's needs around access and experience, and how the system can best use emerging technologies to engage consumers. Under Matt's leadership, the Piedmont team has won more than three dozen local and national marketing awards since 2013, and he has been individually recognized as AMA/Atlanta Corporate Marketer of the Year and American Business Awards Marketing Executive of the Year. Twitter: https://twitter.com/gove LinkedIn: https://www.linkedin.com/in/mattgove3/ About Kyruus Kyruus delivers proven provider search and scheduling solutions that help hospitals and health systems match patients with the providers best suited to care for them. The ProviderMatch suite of solutions—for consumers, access centers, and referral networks—enables a consistent patient experience across multiple points of access, while aligning provider supply with patient demand. The company's proprietary provider data management platform forms the foundation of its solutions, powering them with accurate data by coupling data processing with administrative applications. To find out why a Better Match Means Better Care, please visit www.kyruus.com. You can find the rest of our HIMSS18 Interviews here. Subscribe to Weekly Updates If you like what we're doing here, then please consider signing up for our weekly newsletter. You'll get one email from me each week detailing: New podcast episodes and blog posts. Content or ideas that I've found valuable in the past week. Insider info about the show like stats, upcoming episodes and future plans that I won't put anywhere else.   Plain text and straight from the heart :) No SPAM or fancy graphics and you can unsubscribe with a single click anytime. The #HCBiz Show! is produced by Glide Health IT, LLC in partnership with Netspective Media. Music by StudioEtar